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Introduction
By adulthood, 60-90% of the population are seropositive for herpes simplex virus (HSV-1). 1 The host immune response to a primary HSV-1 infection in mice [2] [3] [4] [5] [6] [7] and to a much lesser extent in humans [8] [9] [10] [11] [12] confers a protective effect on subsequent HSV-1 infection. In vitro, antibodies and leukocytes are effective in blocking or eliminating HSV infection. 13, 14 Even so, previous studies of HSV tumor therapy have only utilized naive animals, lacking prior exposure to HSV. Therefore, the cytopathic, antitumor effect of attenuated HSV vectors has not been investigated in HSV pre-exposed, seropositive animals.
We have developed an attenuated, multi-mutated, replication-competent HSV vector, termed G207, which has proved efficacious in treating human [15] [16] [17] and mouse 18 malignant tumors. G207 has deletions at both ␥34.5 (RL1) loci 19 and an insertion of the E. coli lacZ gene inactivating the ICP6 gene (UL39), 20 which results in attenuated neurovirulence, temperature sensitivity, ganciclovir hypersensitivity, and expression of an easily detectable histochemical marker (␤-galactosidase). 15 Cytopathic effect has been demonstrated in vitro in multiple human tumor cell lines. Intraneoplastic inoculation of G207 into subcutaneous (s.c.) or intracerebral (i.c.) tumors in mice leads to decreased tumor growth and prolonged survival. G207 is non-pathogenic when inoculated intracerebrally in mice and in HSV-sensitive nonhuman primates, 15 and is currently undergoing clinical evaluation for the treatment of recurrent glioma.
To model more closely a HSV-seropositive human's response to HSV-mediated tumor therapy, an immune response to HSV in mice was evoked with wild-type HSV-1, and G207 was subsequently tested as a viral tumor therapy. Infection of mice with live, replicationcompetent or replication-defective mutants of HSV induces long-lived immunity, involving both T and B cells. [21] [22] [23] This humoral response in mice after HSV infection appears to parallel the response found in humans. 9, [24] [25] [26] There are rapid, sensitive methods for detecting anti-HSV antibodies such as ELISA (enzymelinked immunosorbent assay) and virus neutralization assay (NA). We used two strains of mice, A/J and BALB/c, to examine how prior HSV exposure and seropositivity in two different genetic backgrounds affects viral tumor therapy. A/J is more susceptible to lethal HSV infection than BALB/c. 27 For these studies, we used two subcutaneous tumor models, CT26, a colorectal tumor cell line syngeneic to BALB/c mice that is poorly immunogenic, 28, 29 and N18, a neuroblastoma tumor cell line syngeneic to A/J mice that is moderately immunogenic (Todo T, unpublished data). N18 cells are moderately sensitive to G207-mediated cell death and replication in vitro (Todo T, unpublished data), whereas, CT26 cells are less sensitive. 30 As opposed to the situation in immune-deficient athymic mice, where direct G207 oncolytic activity is important for tumor destruction, 17 tumor growth inhibition in immune-competent mice involves the induction of an antitumor immune response. 18, 30 Therefore, tumor cells that do not support extensive G207 replication in vitro, such as CT26, are still susceptible to G207-mediated tumor growth inhibition in vivo.
Results

HSV exposure and seropositivity
To expose animals to HSV-1 in order to induce seropositivity, BALB/c and A/J female mice were injected intraperitoneally with wild-type HSV-1 KOS (3 × 10 4 plaque forming units (p.f.u.) and 3 × 10 3 p.f.u., respectively). Intraperitoneal (i.p.) infection of mice results in higher antibody levels than other routes of inoculation (i.p. Ͼ footpad Ͼ Ͼ subcutaneous), and females have higher levels than males by the i.p. route. 24 On days 7 and 14 after infection, there was no detectable antibody response Figure 1 , Table 1 ). The IgM titer decreased considerably by day 47 in BALB/c mice ( Figure 1 ).
In vivo treatment of subcutaneous (s.c.) tumor The effect of G207 inoculation on s.c. tumor growth (CT26 and N18) in seropositive and naive mice (BALB/c and A/J) was examined. Established s.c. tumors (5-6 mm in maximal diameter) were treated with a single intraneoplastic inoculation of G207 or mock-extract. In mockextract-treated mice, tumors grew steadily until the tumor burden became too large (Ͼ24 mm in maximal diameter) and animals were killed, irrespective of their prior exposure status (Figure 2 ). One N18 tumor mass After death Pre-exposed 1:280 ± 110 (n = 5) 1:120 ± 30 (n = 6) G207-treated 1:160 ± 40 (n = 3) 1:30 ± 10 (n = 4) Pre-exposed/G207-treated 1:450 ± 120 (n = 3) 1:210 ± 120 (n = 5) Control a (n = 6) a (n = 5) Virus infection was determined by plaque assay of KOS or G207 on Vero cells. The neutralization titer represents the dilution of serum needed to reduce the number of plaques by at least 50% compared with the plaque number in the absence of serum. This was determined from a serum dilution curve (130, 90, 270, 810, 2430). G207-treated A/J mice were killed on day 21 (naive, n = 1), day 35 (pre-exposed, n = 1) and day 115 (naive, n = 2; pre-exposed, n = 2) after treatment. G207-treated tumor-bearing mice produced less neutralizing antibodies than KOS pre-exposed mice. a The serum of control mice which were not inoculated with KOS or G207 did not neutralize 50% of KOS at any dilution. Number refers to the individual animal. ND, not done.
was considerably smaller (54 mm 3 ) than the other tumors (у80 mm 3 ) at the initiation of treatment and never grew after mock treatment. G207 inoculation inhibited the growth of both CT26 and N18 s.c. tumors, in seropositive and naive animals. The mean tumor growth ratio was significantly different between G207-treated and control groups on day 16 after treatment, when the mock-treated animals began to be killed (P Ͻ 0.003; likelihood ratio test; Figure 2a . The immune status of the mice to HSV had no effect on their survival.
Antibody response to HSV after tumor therapy
Mice not exposed to HSV did not demonstrate an anti-HSV antibody response ( Figure 3 ). On the other hand, all mice challenged with HSV either by pre-exposure with KOS and/or by G207 treatment had an antibody response against KOS (as demonstrated by NA (Table 1) and ELISA ( Figure 3) ) and against G207 (as demonstrated by NA (Table 1 ) and ELISA (data not shown)). Anti-HSV antibody titers remained high to day 115 in the four G207-treated A/J mice that were tested, both in preexposed and naive animals ( Table 1 ). The humoral response was much greater in the KOS immunized mice than in the G207-treated non-immunized mice. G207-treated non-immunized A/J mice mounted a larger antibody response to HSV than BALB/c mice ( Figure 3 , Table 1 ), yet G207 inoculation was more effective at increasing survival of N18 tumor-bearing animals than CT26 tumor-bearing BALB/c mice ( Figure 2 ).
Multiple G207 intratumoral inoculations
In light of the above results, we tested whether multiple G207 intratumoral inoculations would improve antitumor efficacy. A 10-fold lower dose of G207 (10 6 p.f.u.) was used to increase potential tumor growth differences, and so that even after multiple inoculations the total amount of virus inoculated would be less than in the previous single inoculation studies (10 7 p.f.u.). When the CT26 s.c. tumors reached approximately 6 mm in maximal diameter (10 days later), the mice were randomly divided into three equal groups (n = 8) receiving either a single G207 inoculation, multiple G207 or mock-extract inoculations (biweekly for 3 weeks). Tumors treated with a single G207 inoculation had a decreased growth rate, although on day 24 after treatment, the mean tumor growth ratio was not significantly different between the single G207-treated and mock-treated groups (P = 0.17; likelihood ratio test; Figure 4 left). The mock-treated mice did not survive past day 34, whereas the single G207 inoculated mice survived for a longer (up to day 46), although not quite significant time (P = 0.22; Wilcoxon test; Figure 4 right). A more striking difference in tumor growth inhibition was seen when the multiple G207 inoculation group was compared with both the single and mock treatment groups (P Ͻ 0.00001; likelihood ratio test; Figure 4 left). Six of eight mice in the multiple G207 treatment group were cured of their tumors, after being followed for over 5 months from the day of tumor implantation. The two mice where the tumor continued to grow had a significant reduction in tumor growth and prolonged survival. One was killed on day 65 and the other on day 84 due to large tumor size (Figure 4 right).
Discussion
G207 is currently in clinical trial for human glioma, and this and other related herpes vectors are being considered for clinical trials of non-nervous system tumors. We have previously shown that G207 is efficacious in inhibiting the growth of established human tumors in athymic mice and established mouse tumors in syngeneic mice, and is avirulent in mice and HSV-sensitive nonhuman primates after intracerebral inoculation. [15] [16] [17] [18] However, potential clinical recipients of this form of tumor therapy will be immune-competent or immune-suppressed due to steroid treatment, and likely HSV seropositive. To address whether prior HSV exposure and seropositivity will be a confounding factor for this therapeutic approach, we examined the effect of prior HSV exposure and seropositivity in two mouse strains on G207-mediated tumor therapy. Several factors may affect G207 efficacy in the HSV immunized group: humoral and/or cell-mediated immune responses could neutralize the spread and cytopathic effect of G207, thereby reducing therapeutic efficacy; alternatively, immunization could induce an inflammatory response in the tumor against HSV that could stimulate an antitumor immune response and thereby increase therapeutic efficacy. For example, immunecompetent mice infected with adenovirus vectors were unable to be reinfected efficiently for 30 days due to neutralizing viral antibodies, and cells infected with the virus
Figure 3 ELISA for HSV antibodies in serum of tumor-bearing BALB/c (upper) and A/J (lower) mice. Serum was obtained from s.c. tumor-bearing mice at the time they were killed. Animals were killed based on their tumor burden, with the exception of four G207-treated A/J mice (two pre-exposed and two naive) which were killed on day 115 after their tumor had regressed to a scar. The number of BALB/c animals per group was: preexposed, mock-extract-treated (n = 6); pre-exposed, G207-treated (n = 5); naive, mock-extract-treated (n = 5); and naive, G207-treated (n = 4). For A/J: pre-exposed, mock-extract-treated (n = 5); pre-exposed, G207-treated (n = 3); naive, mock-extract-treated (n = 6); and naive, G207-treated (n = 3). The number of animals in the G207-treated groups was less than the Mock because of the long-term survivors. Bars represent the means ± s.e.m.
were rapidly eliminated due to humoral and cellular response to viral antigen. 31 We have shown that G207 inoculation of s.c. tumors in immune-competent animals is able to induce a systemic, tumor-specific immune response that likely involves CD8 + cytotoxic T cells. 18, 30 There are a number of anecdotal reports in the literature of tumor regression during viral infection, 32, 33 as well as experimental models where virus infected tumor cells elicited antitumor immunity. 34, 35 A number of studies using live HSV vaccination in different mouse models suggests that anti-HSV antibody principally limits viral invasion of the CNS, whereas T cells, particularly CD4 + , inhibit primary viral replication and protect against latent infection.
22,36-39 However, the host immune response does not seem to be sufficient to block acute viral replication. In humans, recurrences of HSV infections occur frequently, even in the presence of high antibody levels and cellular immunity. 8, [40] [41] [42] [43] In vaccinated mice, under conditions of protective immunity, viral replication at the site of HSV infection is high in the first couple of days after challenge. 23 Such acute viral replication may be sufficient to elicit the antitumor response we observed in seropositive mice.
We used two genetically distinct strains of mice, A/J and BALB/c, with differing sensitivity to HSV infection, 27 to account for possible genetic variability in the immune response. Both strains of mice produced similar levels of anti-HSV antibodies after i.p. infection, in concurrence with previous studies that found no difference in either humoral or cellular immune response between HSVresistant or susceptible mice. 44, 45 G207 intratumoral inoculation elicited a decreased antibody response when compared with KOS i.p. inoculation. This could be due to the greatly decreased virulence and/or viral replication of G207, the effect of the ICP6 or ␥34.5 mutations, the route of infection, or possible immune-suppressive attributes of the tumor.
There was no significant difference in the efficacy of G207 tumor therapy between HSV pre-exposed and nonexposed mice, despite differences between the two tumor models. A/J syngeneic N18 neuroblastoma tumors, which are moderately sensitive to G207 infection (T Todo et al, unpublished results) and immunogenic, were cured approximately 70% of the time after G207 intratumoral inoculation. BALB/c syngeneic CT26 colon carcinoma tumors, cured less than 10% of the time, are not very susceptible to G207 infection in vitro and in vivo 30 and poorly immunogenic. 28 The mechanisms by which G207 inhibits tumor growth in these models is complex and likely multi-factorial.
Herrlinger et al 46 have examined the effect of prior HSV exposure on marker gene transfer, using replication-competent HSV ICP6 mutant hrR3, in a rat intracranial D74 glioma model. They found an approximate five-to 10-fold decrease in the area of tumor expressing the marker gene. 46 We did not examine the extent of G207 infection of tumor cells in vivo in seropositive mice. They also found that there was no difference in the efficacy of tumor treatment, whether animals were seropositive or not. Unfortunately, the D74 tumor cells are resistant to hrR3 infection, which had only a small impact on tumor growth. 46 The N18 and CT26 tumor models are more sensitive to G207 infection and there was a large impact on tumor growth, with or without prior HSV exposure. HSV immunity involves all arms of the host immune system (B cells, CD4
+ and CD8 + T cells, NK cells, etc). 22, 47, 48 It will be of interest to determine the contribution of the various immune components in the balance between stimulating G207-mediated tumor destruction and limiting G207 infection. These experiments suggested that prior G207 treatment should not preclude additional inoculations. Therefore, CT26 s.c. tumors, which did not respond as well as N18 tumors to G207 therapy, were treated with six injections of low-titer G207 (10 6 p.f.u.) over a 3 week period. This treatment regimen was far superior to a single injection of G207. Furthermore, when compared with the previous experiment with a single injection of high-dose G207 (10 7 p.f.u.), multiple injections of low dose G207 increased the 'cure' rate from 10% to 75% of tumor-bearing mice. This may reflect a synergistic effect of multiple intratumoral G207 inoculations inducing a tumor-specific immune response and possibly overcoming any inhibitory effect of induced humoral and cell-mediated immunity to HSV over the 3 weeks of G207 injections. It could also reflect increased cell killing due to multiple tumor cell infections over a period of time. In contrast, gene therapy studies with adenovirus show that the virus induces a strong immune response (both neutralizing antibodies and cell-mediated) which blocks subsequent gene delivery with adenovirus vectors. [49] [50] [51] [52] The use of animal models that reflect the likely patient status with regards to the virus vector is important in avoiding adverse clinical outcomes. The HSV seropositive tumor-bearing mice described here provide a useful model for the likely clinical recipients of HSV gene therapy. These studies suggest that the HSV immune status of patients is unlikely to affect G207 tumor therapy. Moreover, multiple treatments with G207 are far superior to a single treatment and should be considered for clinical evaluation in the treatment of tumors.
Materials and methods
Viruses and cells HSV-1 wild-type strain KOS1.1 (obtained from D Knipe, Harvard Medical School, Boston, MA, USA) and G207, an HSV-1 mutant containing deletions in both copies of the ␥34.5 gene and an E. coli lacZ insertion inactivating the ICP6 gene, 15 were prepared by infection of African green monkey kidney (Vero) cell cultures at a multiplicity of infection (MOI) of 0.02 at 34°C as described. 15 Mockextracts were prepared identically, except that buffer was used in place of virus during the infection step. G207 (column purified) was obtained from Neuro Vir (Vancouver, BC, Canada). After cell lysis and low speed centrifugation, the lysate was filtered (0.45 m), purified over a size exclusion column (Sephacryl S500), pelleted by ultracentrifugation (80 000 g for 80 min), resuspended in PBS/10% glycerol and filtered (0.2 m). Titration of both viruses was performed by plaque assay. CT26 (H-2 d ), a colon epithelial tumor cell line derived by intrarectal injections of N-nitro-N-methylurethan in a female BALB/c mouse 53, 54 was provided by Dr NP Restifo (NIH, Bethesda, MD, USA) and N18, a murine neuroblastoma tumor cell line was provided by Dr K Ikeda (Tokyo Institute of Psychiatry, Japan). Cell lines were grown in DMEM containing 10% calf serum (Hyclone, Logan, UT, USA), glucose (4.5 g/l), penicillin-streptomycin (Sigma Chemical, St Louis, MO, USA) and glutamine.
Animal studies Six-week-old female BALB/c and A/J mice were purchased from the National Cancer Institute (Frederick, MD, USA). All animal procedures were approved by the Georgetown University Animal Care and Use Committee. For surgical procedures, each mouse was anesthetized with a 0.25-0.30 ml i.p. injection of a solution consisting of 84% bacteriostatic saline, 10% sodium pentobarbital (50 mg/ml; Abbott Laboratories, Chicago, IL, USA), and 6% ethyl alcohol.
HSV exposure
Mice were immunized by i.p. injection of HSV-1 KOS in 0.2 ml of PBS. BALB/c mice (n = 13) were injected with 3 × 10 4 p.f.u. and A/J mice (n = 13) with 3 × 10 3 p.f.u. This was followed 27 days later by a second i.p. injection of HSV-1 KOS (1 × 10 6 p.f.u. for BALB/c and 5 × 10 5 p.f.u. for A/J mice). This i.p. dosage was previously found to be sub-lethal. The A/J mice received a smaller dose of HSV-1 than the BALB/c mice due to their lower LD 50 . 24, 27 The control groups (n = 13) were injected similarly with saline.
Antibody titers
To verify a humoral immune response, blood was obtained on days 7, 14, 38 and 47 after infection by retro-orbital bleeding after methoxyflurane anesthesia. Before any mice were killed, they were bled from a carotid artery after anesthesia with 0.30 ml i.p. injection of sodium pentobarbital solution. Blood was allowed to clot overnight at 4°C, and the serum recovered by centrifuging clotted blood at 16 000 g for 10 min at 4°C.
Enzyme-linked immunosorbent assay (ELISA)
Ninety-six-well plates were coated with 0.1 ml of HSV-1 KOS (2 × 10 5 p.f.u. in PBS) and stored overnight at 4°C. The wells were blocked for 2 h at 37°C with PBS/0.1% bovine serum albumin (BSA). Plates were washed with three additions of PBS/0.05% Tween 20 between each step. Serum was diluted in ELISA buffer (PBS/0.1% BSA/0.05% Tween 20), added to wells and then incubated for 3 h at 37°C. Horseradish peroxidase (HRP)-conjugated goat anti-mouse IgM or goat anti-mouse IgG (both diluted 1:10 000; ICN Biomedicals, Aurora, OH, USA) was added (100 l per well) and incubated overnight at 4°C. After washing, wells were incubated with tetramethylbenzidine (TMB) (KPL, Gaithersburg, MD, USA) for 30 min and the reaction stopped by the addition of 100 l of 0.18 m sulfuric acid. The absorbance at 450 nm was determined in a Biorad (Hercules, CA, USA) plate reader.
Virus neutralization assay (NA)
Heat inactivated mouse serum (56°C for 30 min) was serially diluted in PBS/1% heat inactivated fetal calf serum (IFCS), mixed with an equal volume of KOS (100 p.f.u.) for a total volume of 100 l, and incubated for 1 at 37°C. This mixture was then used to infect monolayers of VERO cells, and the number of plaques counted 2 to 3 days later after fixing with methanol and staining with Giemsa.
Subcutaneous tumor model CT26 cells (1 × 10 5 ) were implanted s.c. in the left flanks of BALB/c immunized (n = 13) and non-immunized (n = 14) mice, and N18 cells (1 × 10 7 ) were implanted s.c. in A/J immunized (n = 13) and non-immunized (n = 14) mice (day 57 after immunization). When the s.c. tumors were approximately 6 mm in maximal diameter (approximately 7-10 days after implant), mice were randomly divided into two groups (n = 5 or 6): mock-and G207-treated. The mice were inoculated intratumorally with G207 (1 × 10 7 p.f.u./20 l) or 20 l mock-extract. For the multiple inoculation experiment, mice harboring s.c. tumors approximately 5 mm in maximal diameter were randomly divided into three groups (n = 8 per group) and intratumorally inoculated with G207 (1 × 10 6 p.f.u./20 l) once or six times (biweekly for 3 weeks), or with 20 l of buffer six times (biweekly for 3 weeks).
Tumor growth was determined by measuring the tumor volume (length × width × height) twice weekly. Statistical differences in growth ratio were assessed using a likelihood ratio test, where a longitudinal model was fit to a graph of our data. 55 Survival of mice was analyzed by Kaplan-Meier method and its statistical evaluation by Wilcoxon test. Mice were killed when they appeared moribund or their tumor diameter reached 24 mm; the date of they were killed was recorded as the date of death for survival studies.
